Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
(2010) In Archives of Neurology 67(2). p.217-223- Abstract
- BACKGROUND: Abnormal cerebrospinal fluid (CSF) biomarker levels predict development of Alzheimer disease with good accuracy and are thought to precede cognitive deterioration. OBJECTIVE: To investigate whether changes in CSF biomarker levels over time in healthy older adults are associated with a concurrent decline in cognitive performance. DESIGN: Retrospective analysis of longitudinal CSF biomarker levels and clinical data. SETTING: A combined academic dementia disorder research center and dementia clinic. PARTICIPANTS: Thirty-seven cognitively healthy older volunteers (mean age, 73 years). MAIN OUTCOME MEASURES: Longitudinal CSF total tau protein, hyperphosphorylated tau protein 181, and beta-amyloid(1-42) protein levels and cognitive... (More)
- BACKGROUND: Abnormal cerebrospinal fluid (CSF) biomarker levels predict development of Alzheimer disease with good accuracy and are thought to precede cognitive deterioration. OBJECTIVE: To investigate whether changes in CSF biomarker levels over time in healthy older adults are associated with a concurrent decline in cognitive performance. DESIGN: Retrospective analysis of longitudinal CSF biomarker levels and clinical data. SETTING: A combined academic dementia disorder research center and dementia clinic. PARTICIPANTS: Thirty-seven cognitively healthy older volunteers (mean age, 73 years). MAIN OUTCOME MEASURES: Longitudinal CSF total tau protein, hyperphosphorylated tau protein 181, and beta-amyloid(1-42) protein levels and cognitive assessments at baseline and at follow-up 4 years later. RESULTS: Low levels of CSF beta-amyloid(1-42) protein at follow-up were associated with decreased delayed word recall score on the Alzheimer Disease Assessment Scale-cognitive subscale (r(s) = -0.437, P < .01) and with slower results on A Quick Test of Cognitive Speed (r(s) = -0.540, P < .001). Individuals with a decrease during the 4-year study of 15% or more in CSF beta-amyloid(1-42) protein level performed worse on the Alzheimer Disease Assessment Scale-cognitive subscale delayed word recall (z = -2.18, P < .05) and A Quick Test of Cognitive Speed (z = -2.35, P < .05) at follow-up. An increase over time of 20% or more in CSF hyperphosphorylated tau protein 181 level correlated with slower results on A Quick Test of Cognitive Speed at follow-up (z = -2.13, P < .05). Furthermore, the presence of the APOE-epsilon4 (OMIM 107741) allele was associated with a greater longitudinal decrease in CSF beta-amyloid(1-42) protein level (chi(2) = 10.47, P < .05) and with a higher CSF total tau protein level at follow-up (chi(2) = 8.83, P < .05). No correlation existed between baseline CSF biomarker levels and baseline or follow-up cognitive scores. CONCLUSIONS: In this group of healthy older adults, changes in CSF biomarker levels previously associated with Alzheimer disease correlated with a decline in cognitive functions. Changes in CSF biomarker levels may identify early neurodegenerative processes of Alzheimer disease. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1552786
- author
- Stomrud, Erik LU ; Hansson, Oskar LU ; Zetterberg, Henrik ; Blennow, Kaj ; Minthon, Lennart LU and Londos, Elisabet LU
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Archives of Neurology
- volume
- 67
- issue
- 2
- pages
- 217 - 223
- publisher
- American Medical Association
- external identifiers
-
- wos:000274374600012
- pmid:20142530
- scopus:76149101242
- ISSN
- 0003-9942
- DOI
- 10.1001/archneurol.2009.316
- language
- English
- LU publication?
- yes
- id
- 57cac646-717f-4a0f-ad70-cf3c72558fec (old id 1552786)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/20142530?dopt=Abstract
- date added to LUP
- 2016-04-04 08:08:29
- date last changed
- 2023-11-15 06:46:43
@article{57cac646-717f-4a0f-ad70-cf3c72558fec, abstract = {{BACKGROUND: Abnormal cerebrospinal fluid (CSF) biomarker levels predict development of Alzheimer disease with good accuracy and are thought to precede cognitive deterioration. OBJECTIVE: To investigate whether changes in CSF biomarker levels over time in healthy older adults are associated with a concurrent decline in cognitive performance. DESIGN: Retrospective analysis of longitudinal CSF biomarker levels and clinical data. SETTING: A combined academic dementia disorder research center and dementia clinic. PARTICIPANTS: Thirty-seven cognitively healthy older volunteers (mean age, 73 years). MAIN OUTCOME MEASURES: Longitudinal CSF total tau protein, hyperphosphorylated tau protein 181, and beta-amyloid(1-42) protein levels and cognitive assessments at baseline and at follow-up 4 years later. RESULTS: Low levels of CSF beta-amyloid(1-42) protein at follow-up were associated with decreased delayed word recall score on the Alzheimer Disease Assessment Scale-cognitive subscale (r(s) = -0.437, P < .01) and with slower results on A Quick Test of Cognitive Speed (r(s) = -0.540, P < .001). Individuals with a decrease during the 4-year study of 15% or more in CSF beta-amyloid(1-42) protein level performed worse on the Alzheimer Disease Assessment Scale-cognitive subscale delayed word recall (z = -2.18, P < .05) and A Quick Test of Cognitive Speed (z = -2.35, P < .05) at follow-up. An increase over time of 20% or more in CSF hyperphosphorylated tau protein 181 level correlated with slower results on A Quick Test of Cognitive Speed at follow-up (z = -2.13, P < .05). Furthermore, the presence of the APOE-epsilon4 (OMIM 107741) allele was associated with a greater longitudinal decrease in CSF beta-amyloid(1-42) protein level (chi(2) = 10.47, P < .05) and with a higher CSF total tau protein level at follow-up (chi(2) = 8.83, P < .05). No correlation existed between baseline CSF biomarker levels and baseline or follow-up cognitive scores. CONCLUSIONS: In this group of healthy older adults, changes in CSF biomarker levels previously associated with Alzheimer disease correlated with a decline in cognitive functions. Changes in CSF biomarker levels may identify early neurodegenerative processes of Alzheimer disease.}}, author = {{Stomrud, Erik and Hansson, Oskar and Zetterberg, Henrik and Blennow, Kaj and Minthon, Lennart and Londos, Elisabet}}, issn = {{0003-9942}}, language = {{eng}}, number = {{2}}, pages = {{217--223}}, publisher = {{American Medical Association}}, series = {{Archives of Neurology}}, title = {{Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.}}, url = {{http://dx.doi.org/10.1001/archneurol.2009.316}}, doi = {{10.1001/archneurol.2009.316}}, volume = {{67}}, year = {{2010}}, }